Day 28/100
Ever wonder how the pills in your medicine cabinet actually get made? We usually just look at the logo on the bottle, but the foundational chemistry happens much earlier in the supply chain.

I've been analyzing Divi’s Laboratories, a massive operation in Vishakhapatnam that acts as the quiet backbone for 12 of the world's top 20 pharma innovators.

(Quick disclaimer: I am not a SEBI-registered advisor, so please don't take this as investment advice! I'm just sharing some fascinating business mechanics).

Here is what makes their model so resilient:
The Hidden Moat: Once an innovator builds a clinical trial around Divi's specific chemistry, switching suppliers can trigger massive regulatory delays and cost millions in forgone revenue.

Looking Beyond PE: Trailing PE misses the mark because custom synthesis revenue is milestone-based. Their ~20.45% ROCE is a much stronger signal of their capital quality.

Global Infrastructure: As global supply chains actively move to reduce their dependency on China, Divi's functions more like an irreplaceable infrastructure asset than a standard pharma stock.

Check out my full deep dive into the supply chain no one draws correctly to learn more!
https://open.substack.com/pub/spicapitalresearch/p/divilabs-the-infrastructure-that
Found this interesting?
Join our Community Channel for FREE on WhatsApp
https://whatsapp.com/channel/0029VbCUIyF3AZNIZAA6GXOK

Also if you are on insta (of course you are), Follow me on Insta.
https://instagram.com/spicapitalresearch

#Investing #PharmaSector #CDMO #BusinessStrategy #StockMarket #100DaysWithTVS